 Home > Medical News > Latest Medical News > Hengrui PD-1 new indication approved: first-line treatment of nasopharyngeal carcinoma

Hengrui PD-1 new indication approved: first-line treatment of nasopharyngeal carcinoma

 Last Update: 2021-06-22
 Source: Internet
 Author: User

Tags

food drug administration jobs

pd 1 pathway

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 10, the official website of the State Food and Drug Administration showed that the new indication for Hengrui Carrelizumab for Injection (Registration Classification: 2.
2) has been approved by the NMPA
.

The approved indications are: combined cisplatin and gemcitabine for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma
.

This is the sixth indication approved for Karelizumab

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Hengrui PD-1 new indication is about to be approved: first-line treatment of nasopharyngeal carcinoma

06-17

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Hengrui PD-1 new indication approved: first-line treatment of nasopharyngeal carcinoma

Related Articles

Hengrui PD-1 new indication is about to be approved: first-line treatment of nasopharyngeal carcinoma